Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience

Eur J Haematol. 2018 Mar;100(3):308-314. doi: 10.1111/ejh.13015. Epub 2018 Jan 11.

Abstract

Objective: Second allogeneic hematopoietic cell transplantation (HCT) may be indicated following relapse or graft failure following first HCT. Our retrospective single-center study sought to investigate parameters that influence post-second allogeneic HCT survival.

Method: We investigated 92 patients who underwent second allogeneic HCT between 1980 and 2016 for relapse or graft failure following first HCT. Median age at second HCT was 41 years (range 16-68), performed for relapse in 59 patients (64%) and for graft failure in 33 patients (36%).

Results: On univariate analysis, 3-year OS of the entire cohort was 35% (95% CI=25-45). Eastern Cooperative Oncology Group (ECOG) score (3-year OS 48% for ECOG 0-1, 18% for ECOG 2-3, P=.0006), second HCT indication (3-year OS 43% for relapse, 20% for graft failure, P=.02), time from first HCT to relapse/graft failure (3-year OS for <12months 21%, for ≥12months 46%, P=.009), and conditioning intensity (3-year OS for MA 42% vs other regimens 23%, P=.08) significantly influenced OS. Multivariable analysis confirmed ECOG score (HR=2.15 for ECOG 2-3, 95% CI=1.32-3.51, P=.002) and second HCT indication (HR=1.67 for graft failure, 95% CI=1.02-2.75, P=.04) to independently influence survival.

Conclusion: Second HCT may offer long-term survival particularly to patients with good performance status who relapse post-first HCT.

Keywords: allogeneic HCT; second transplant; single center.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anemia, Aplastic / immunology
  • Anemia, Aplastic / mortality
  • Anemia, Aplastic / pathology
  • Anemia, Aplastic / therapy*
  • Female
  • Graft Rejection / diagnosis*
  • Graft Rejection / immunology
  • Graft Rejection / mortality
  • Graft Rejection / pathology
  • Graft Survival / physiology*
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Myeloablative Agonists / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Recurrence
  • Retrospective Studies
  • Survival Analysis
  • Transplantation Conditioning / methods
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Myeloablative Agonists